RT Journal Article
SR Electronic
T1 Evolving impact of the COVID-19 pandemic in chronic dialysis recipients over the course of pandemic waves and COVID-19 vaccination rollout: a French national study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.05.24305315
DO 10.1101/2024.04.05.24305315
A1 Leye, Elhadji
A1 El Karoui, Khalil
A1 Delory, Tristan
A1 Espagnacq, Maude
A1 Khlat, Myriam
A1 Le Coeur, Sophie
A1 Lapidus, Nathanaël
A1 Hejblum, Gilles
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/06/05/2024.04.05.24305315.abstract
AB Background This observational study aims to assess the impact of the pandemic on the evolving of kidney transplantations, survival, and vaccination in chronic dialysis recipients (CDR) over the COVID-19 pandemic subperiods.Methods Using the French national health claims database, incident persons with end stage kidney disease in years 2015 to 2021 treated with dialysis were followed-up until December 31, 2022. Kidney transplantion and survival over pandemic subperiods versus the prepandemic period were investigated using longitudinal models with time-dependent covariates. Moreover, the impact of cumulative doses of COVID-19 vaccine on hospitalization and survival were compared between CDR and matched-control individuals.Findings Follow-up of the 71,583 CDR and 143,166 controls totalized 639,341 person-years (CDR: 184,909; controls: 454,432). The likelihood of receiving a kidney transplant decreased during all pandemic subperiods except one. Mortality in CDR increased during the 3 wave subperiods (hazard ratio (HR [95% confidence interval]): 1.19 [1.13–1.27], 1.19 [1.15–1.23], and 1.12 [1.07–1.17], respectively). While vaccine coverage declined with each booster dose, receiving such doses was associated with lower risks of COVID-19-related hospitalization (0.66 [0.56–0.77], 0.83 [0.72–0.94] for 1st booster versus 2nd dose and 2nd booster versus 1st booster, respectively) and death (corresponding HR: 0.55 [0.51–0.59], 0.88 [0.83–0.95]). Evolving patterns in mortality and vaccination outcomes were similar in CDR and controls.Interpretation The impact of the pandemic in CDR was not specific of the kidney disease per se. Study results also suggest future research aimed at increasing adherence to vaccine booster doses.Funding Initiative Économie de la Santé de Sorbonne Université (Idex Sorbonne Université, programmes Investissements d’Avenir) ; Ministère de la Solidarité et de la Santé (PREPS 20-0163).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Initiative Economie de la Sante of Sorbonne Universite (Idex Sorbonne Universite, programmes Investissements Avenir), and by the Ministere de la Solidarite et de la Sante (Programme de Recherche sur la Performance du Systeme des Soins, PREPS 20-0163). The sponsor and the funders had no role in study design, data collection and analysis, interpretation of data, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SNDS is a set of strictly anonymous databases comprising all mandatory national health insurance reimbursement data. Since June 30, 2021 INSERM has direct access to the SNDS. This permanent access is provided according French Decree No. 2016-1871 of December 26, 2016 relating to the processing of personal SNDS data and French law articles Art. R. 1461-1325 and 14. This study was declared prior to its initiation to the CepiDc-INSERM registry of studies requiring the use of the SNDS. In accordance with national legislation and EU General Data Protection Regulation, written informed consent for participation was not required for this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAccording to the principles of data protection and French regulations, the authors cannot publicly release the data from the French National Health Data System (SNDS). However, any person or structure, public or private, for-profit or non-profit, can access SNDS data upon authorization from the French Data Protection Office (CNIL, Commission Nationale de l’Informatique et des Libertés) to carry out a study, research, or an evaluation of public interest (https://www.snds.gouv.fr/SNDS/Contexte-et-perspectives-reglementaires#).